[Disclosure] Samsung Biologics (207940) Designated as Short-Selling Overheated Stock… Short-Selling Banned on January 23 for 1 Day

Fact Source: Financial Supervisory Service DART / 2026-01-22

Disclosure Type: Designation as Short-Selling Overheated Stock (Short-Selling Ban Applied)

💡 3-Second Summary

Samsung Biologics has been designated as a short-selling overheated stock by the Korea Exchange. Consequently, short-selling transactions will be banned in both the regular and after-hours markets for one day on January 23, 2026, with a possibility of extension if the stock price drops by -5% or more on the day of the ban.

📊 1. [Key Disclosure Content & Major Figures Summary]

• Target Stock: Samsung Biologics (Ticker: KR7207940008 / 207940)
• Designation Date & Ban Period: 2026-01-23 (Applied for 1 day; short-selling resumes on the day following the designation date)
• Market Measure Details:
  • Short-selling transactions are prohibited in the regular and after-hours markets on the designation date.
  • If the stock price falls by -5% or more on the day short-selling is banned, the ban period will be extended.
  • If trading is already suspended on the designation date, no separate measures will be taken under this rule.
• Exempted Transactions: Liquidity providing (LP) orders, market making (MM) orders, hedging transactions for the liquidity provision of ELW, ETF, and ETN products, and hedging transactions for market making in the derivatives market.
• Legal Ground: Article 17 of the KOSPI Market Business Regulations and Article 24-3 of the Enforcement Rules of the same regulation.
• Other Details: The disclosure text does not state specific reasons for financial performance changes or the underlying drivers behind the surge in short-selling.

📈 2. [Expert View: What This Disclosure Means for Investors]

This filing indicates a temporary regulatory administrative measure issued by the Korea Exchange, rather than any fundamental operational shift, earnings revision, or changes in domestic or international CAPEX. The designation as a short-selling overheated stock confirms that short-selling volumes and transaction values recently spiked beyond statutory thresholds, reflecting a short-term concentration of bearish sentiment or downward technical pressure in the market.

While the one-day ban on January 23 introduces a potential impact that temporary restricts the build-up of new speculative short positions, it does not imply total elimination of short activity due to permitted exemptions for hedging and liquidity provision (LP/MM) orders. Furthermore, the inclusion of an extension clause dependent on a -5% or greater decline on the ban date means intra-day volatility remains a key factor to track. Since the original regulatory text does not explain the specific market drivers behind the short-selling acceleration, investors should treat this event purely as a short-term supply-demand imbalance factor rather than drawing definitive conclusions regarding the stock’s direction.

📝 Editor’s Comment (by K-STOCK Editor)

The designation of Samsung Biologics as a short-selling overheated stock signals that trading supply-demand friction has temporarily spiked to regulatory limits. With short-selling capped for a single day on January 23, immediate downward pressure from speculative shorts may see a potential impact of a brief pause. However, because the ban can trigger an automatic extension if the stock drops by -5% or more during the designated session, intra-day price defense will likely act as a focal point for market participants. Investors should also note that institutional hedging and liquidity-provider flows are legally maintained through regulatory exemptions, meaning sell-side volume is not completely locked. Given that this is a purely technical market-structure event unlinked to underlying corporate performance, maintaining a measured and conservative approach while monitoring the trigger conditions is recommended.

📢 Disclaimer & Source Information

Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).

Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the individual investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.